Research progress in biomarkers of drug-induced liver injury / 临床肝胆病杂志

ABSTRACT

Drug-induced liver injury (DILI) is a major reason for the recall of marketed drugs and the failure of clinical trials. Detection of potential liver injury remains a challenge for clinical management and preclinical drug safety studies. Currently, serum levels of alanine aminotransferase and aspartate aminotransferase are the gold standards for evaluating liver injury. However, these biomarkers are nonspecific and insensitive, and often result in false-positive results. Therefore, researchers have never stopped searching for the biomarkers of DILI with high sensitivity and specificity. This review summarizes recent research progress in the biomarkers of DILI to better predict and diagnose DILI.